Targeting enzymes to cancers - new developments

Bibliography

• PHILPOTT GW, SHEARER WT, BOWER RJ, PARKER CW: Selective cytotoxity of hapten-substituted cells with an antibody-enzyme conjugate. J. Immunol. (1973) 111(3):921–929.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE KD: Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer (1987) 56:531–532.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE KD, SPRINGER CJ, SEARLE F et al.: Cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer (1988) 58:700–703.
   PubMed Web of Science ®Google Scholar
• SENTER PD, SAULNIER MG, SCHREIBER GJ et al.: Anti-tumor effects of antibody-alkaline phosphatase conju-gates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA (1988) 85:4842–4846.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE KD: Developments with targeted enzymes. Tumour Targeting (1998) 3:21–24.
   Google Scholar
• CONNORS TA, WHISSON ME: Cure of mice bearing ad-vanced plasma cell tumours with aniline mustard: the relationship between glucorunidase activity and tu-mour activity. Nature (1966) 210:866–867.
   PubMed Web of Science ®Google Scholar
• BOSSLET K, CZECH J, SEEMAN G et al.: Fusion protein mediated prodrug activation (FMPA) in vivo. In: Epene-tos AA (Ed): Abstracts for 10th Int. Conf on Advances in the Application of Monoclonal Antibodies in Clinical Oncology. Paphos, Cyprus (1993).
   Google Scholar
• RILEY RJ, WORKMAN P: DT-daiphorase and cancer che-motherapy. Biochem. Pharmacol (1992) 43:1657–1669.
   PubMed Web of Science ®Google Scholar
• WU KB, KNOX RJ, SUN XZ et al.: Catalytic properties of NAD (P)H-quinine oxidoreductase-2 (NQ02), a dihydronicontinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. (1997) 347:221–228.
   PubMed Web of Science ®Google Scholar
• MELTON RG, BOYLE JMB, ROGERS GT, BURKE PJ, BAG-SHAWE KD, SHERWOOD RF: Optimisation of small scale coupling of A5B7 monoclonal antibody to car-boxypeptidase G2. J Immunol. Meth. (1993) 158:49–56.
   PubMedGoogle Scholar
• BAGSHAWE KD, SHARMA SK, SPRINGER CJ, ANTONIW P: Antibody directed enzyme prodrug therapy: A pilot scale clinical trial. Tumour Targeting (1995) 1:17–29.
   Google Scholar
• MICHAEL NP, CHESTER KA, MELTON RG et al.: In vitro and in vivo characterisation of a recombinant car-boxypeptidase G2 anti-CEAscEv fusion protein. Im-mununotech. (1996) 2:45–57.
   Google Scholar
• DURAN-REYNOLDS F: Studies in the localisation of dyes and foreign proteins in normal and malignant tissues. Am. J. Cancer (1939) 35:98–107.
   Google Scholar
• DVORAK HF, NAGY JA, DVORAK JT, DVORAK AM: Identi-fication and characterisation of the blood vessels of solid tumours that are leaky to circulating macromole-cules. Am. J. Path. (1988) 133:95–109.
   PubMed Web of Science ®Google Scholar
• MAEDA H, MATSUMOTO T, KONNO T, IWAI K, UEDA M:Tailor-making of protein drugs by polymer conjuga-tion for tumor targeting: a brief review on smancs. J. Protein Chem. (1984) 3:181–193.
   Google Scholar
• SZEKERKE M, WADER, WHISSON ME: The use of macro-molecules as carriers of cytotoxic groups 1: Conju-gates of nitrogen mustards with proteins, polypeptidyl proteins and polypeptides. Neoplasm (1972) 19:199.
   PubMed Web of Science ®Google Scholar
• ROSS WCJ, KHAN AH. Tumour-growth inhibitory nitro-phenylaziridines and related compounds. Chem. Biol. Interactions (1969/70) 1:27–47.
   Google Scholar
• SATCHI R., DUNCAN R: PDEPT: Polymer directed en-zyme prodrug therapy. 10th NCEEORTC Symposium on New Drugs in Cancer Therapy. Amsterdam (1998):58.
   Google Scholar
• SATCHI R, DUNCAN R: PDEPT: Polymer directed en-zyme prodrug therapy - in vitro and in vivo characteri-sation. 3rd International Symposium on Polymer Therapeutics. (1998):312.
   Google Scholar
• YUAN F, DELMAN M, FUKUMURA D et al.: Vascular per-meability in a human tumor xenograft: Molecular size dependence and cut off size. Cancer Res. (1995) 55:3752–3756.
   PubMed Web of Science ®Google Scholar
• HEUSER LS, MILLER FN: Differential macromolecularleakage from the vasculature of tumours. Cancer (1986) 57:461–464.
   PubMed Web of Science ®Google Scholar
• SCHULER JB, FIEBIG HH, SAUSVILLE EA, BURGER AM:Characterisation of vascular permeability in human tumor xenografts. Identification of suitable tumor models to evaluate polymer-conjugates. Proc. Au CR (1998) Abstract 2909.
   Google Scholar
• HUBER BE, RICHARDS CA, KRENITSKY T: Retroviral-mediated gene therapy for the treatment of hepatocel-lular carcinoma: an innovative approach for cancer therapy. Proc. Natl Acad. Sci. USA (1991) 88:8039–8043.
   PubMed Web of Science ®Google Scholar
• MCNEISH I, GREEN NK, GILLIGAN MG et al.: Virus di-rected enzyme prodrug therapy for ovarian and pan-creatic cancer using retrovirally delivered E. coli nitroreducatase and CB1954. Gene Therapy (1998) 5:1061–1069.
   Google Scholar
• MILLER N, VILE R: Targeted vectors for gene therapy.FASEB J (1995) 9:190–199.
   PubMed Web of Science ®Google Scholar
• FREI E. III, TEICHER BA, HOLDEN SA, CATHCART KNS,WANG Y: Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. (1988) 48:4517–6423.
   Google Scholar
• ANTONIW P, SPRINGER CJ, BAGSHAWE KD: et al.: Dispo-sition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br. J. Cancer (1990) 62:909–914.
   Google Scholar
• KNOX RJ, FRIEDLOS F, BOLAND MP: The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Can. Metastasis Rev. (1993) 12:195–212.
   PubMed Web of Science ®Google Scholar
• VAN GROENINGEN CJ, PETERS GJ, PINEDO HM: Reversal of 5-fluorouracil-induced toxicity by oral administra-tion of uridine. Ann. Oncology (1993) 4:317–320.
   PubMed Web of Science ®Google Scholar
• FAESSEL HM, SLOCUM HK, JACKSON RC et al.: Super in vi-tro synergy between inhibitors of dihydrofolate re-ductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Res. (1998) 58:3036–3050.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BAGSHAWE KD, BURKE PJ et al: Antibody-directed enzyme prodrug therapy (ADEPT): A three phase system . Disease Markers (1991) 9:225–231.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BAGSHAWE KD, BURKE PJ et al.: Galactosy-lated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy (ADEPT). Cancer (1994) 73:1114–1120.
   PubMed Web of Science ®Google Scholar
• KERR DE, GARRIGUES US, WALLACE PM: Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase im-munoconjugate. Bioconj Chem. (1993) 4:353–357.
   PubMed Web of Science ®Google Scholar
• THORNBURG RW, DAY JF, BAYNES JW, THORPE SR: Car-bohydrate -mediated clearance of immune complexes from the circulation. J. Biol. Chem. (1980) 255:6820–6825.
   PubMed Web of Science ®Google Scholar
• MARTIN J, STRIBBLING SM, POON GK et al.: Antibody-directed enzyme prodrug therapy: pharmokinetics and plasma levels of prodrug and drug in a Phase I clinical trial. Cancer Chemo. Pharmacol (1997) 40:198–201.
   Google Scholar
• BAGSHAWE KD, NAPIER ME: Early clinical studies with ADEPT. In: Principles ofAntibody Directed Enzyme Prodrug Therapy. Melton RG, Knox R (Eds.), Plenum Press, New York (1998) (In Press).
   Google Scholar
• KHAN TH. ENO-AMMOQUAYE E, SEARLE F, BROWNE PJ, OSBORN HM, BURKE PJ: Novel inhibitor of carboxypep-tidase G2: potential use in antibody-directed enzyme prodrug therapy (ADEPT). (1998) (In Preparation).
   Google Scholar
• SPRINGER CJ, BAGSHAWE KD, SHARMA SK et al.: Abla-tion of human choriocarcinoma xenografts in nudemice by antibody directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer (1991) 27:1361–1366.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, BODEN JA, SPRINGER CJ, BURKE PJ, BAG-SHAWE KD: Antibodydirected Enzyme Prodrug Ther-apy (ADEPT). A three-phase study in ovarian tumour xenografts. Cell Biophys. (1994b) 24/25:219–228.
   Google Scholar
• BLAKEY DC, DAVIES DH, DOWELL RI et al.: Anti-tumoureffects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard drugs. Br. J. Can-cer (1995) 72:1083–1088.
   PubMed Web of Science ®Google Scholar
• WINTER G, MILSTEIN C: Man-made antibodies. Nature (1991) 349:293–299.
   PubMed Web of Science ®Google Scholar
• MURRAY GI, TAYLOR MC, MORAG CE et al: Tumor-specific expression of cytochrome P450 CYPIBIl Can-cer Res. (1997) 37:3026-3031.
   Google Scholar
• SHARMA SK, BAGSHAWE KD, SPRINGER CJ et al.: Humanimmune response to monoclonal antibody-enzyme conjugate in Adept Pilot Scale Clinical Trial. Cell Bio-physics (1993) 21/22:109–120.
   Google Scholar
• WALDMAN H, HALE G, CLARK M et al.: Monoclonal anti-bodies for immunosuppression. Prog. Allergy (1988) 45:16.
   PubMedGoogle Scholar
• DURRANT LG, ROBINS A, MARKMAN RA et al: Abroga-tion of antibody responses in rates to murine mono-clonal antibody 719T/36 by treatment with daunomycin-cis-aconity1-719T/36 conjugates. Cancer Immunol. Immunother. (1989) 28(1)37–42.
   Google Scholar
• LIN JT, BERTINO JR: Update on Trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Investigation (1991) 9(2) :159–172.
   PubMed Web of Science ®Google Scholar
• SCHMITZ JC, GRINDEY GB, SCHULTZ RM, PRIEST DG: Im-pact of dietary folic acid on reduced folates in mouse plasma and tissues. Biochem. Pharmacol (1994). 48:319325.
   Google Scholar
• WALLACE PM, SENTER PD: In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conju-gates in combination with phenol mustard phosphate. Biocong. Chem.. (1991) 2:349–352.
   PubMed Web of Science ®Google Scholar
• SENTER PD: Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer ther-apy. FASEB J (1990) 4:188–193.
   PubMed Web of Science ®Google Scholar
• SENTER PD, SCHREIBER GJ, HIRSCHBERG DL et al.: En-hancement of the in vitro and in vivo anti-tumor activi-ties of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phos-phatase conjugates. Cancer Res. (1989) 49:5789–5792.
   PubMed Web of Science ®Google Scholar
• HAISMA HJ, BOVEN E, VAN MUIJEN M, DE VRIES R, PIN-EDO M: Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol. Immu-nother. (1992) 34:343–348.
   PubMed Web of Science ®Google Scholar
• KUEFNER U, LOHRMANN U, MONTEJANO YD, VITOLS KS,HUENNEKENS FM: Carboxypeptidase-mediated releaseof methotrexate from methotrexate a-peptides. Bio-chemistry (1989) 28:2288–2297.
   Google Scholar
• PERRON MJ, PAGE M: Activation of methotrexate-phenylalanine by monoclonal antibody-carboxypeptidase A conjugate for specific treatment of ovarian cancer in vitro. Br. J. Cancer (1996) 73:281–287.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, BAVETSIAS V, JACKMAN AL et al.: Prodrugs of thymidylate synthase inhibitors: potential for anti-body directed enzyme prodrug therapy (ADEPT). Anti-cancer Drug Des. (1996) 11:625–636.
   PubMedGoogle Scholar
• BAGSHAWE KD: The First Bagshawe Lecture: Towards generating cytotoxic agents at cancer sites. Br. J. Cancer (1989) 60:275–281.
   PubMed Web of Science ®Google Scholar
• DOWELL RI, SPRINGER CJ, DAVIES DH et al.: New mus-tard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to amide link. J. Med .Chem. (1996) 39:1100–1105.
   PubMed Web of Science ®Google Scholar
• MARAIS R, SPOONER RA, LIGHT Y, MARTIN J, SPRINGERCJ: Gene-directed enzyme prodrug therapy with a mus-tard prodrug/carboxypeptidase G2 combination. Can-cer Res. (1996) 56:4735–4742.
   PubMed Web of Science ®Google Scholar
• MARAIS R, SPOONER RA, STRIBBLING SM, LIGHT Y, MAR-TIN J, SPRINGER CJ: A cell surface tethered enzyme im-proves efficiency in gene-directed enzyme prodrug therapy. Nature Biotech. (1997) 15:1373–1377.
   PubMed Web of Science ®Google Scholar
• MANOME Y, WEN PY, CHEN L et al: Gene therapy for ma-lignant gliomas using replication incompentent retro-viral and adenoviral vectors encoding the cytochrome P450-2B1 gene together with cyclosphosphamide. Gene Ther. (1996) 3:513-5 20
   Google Scholar
• WEI MX, TAMIYAT, CHASE M et al.: Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450-2B1 gene. Hum. Gene Ther. (1994) 5:969–978.
   PubMed Web of Science ®Google Scholar
• RAINOV NG, DOBBERSTEIN KU, SENAESTEVES M et al:New prodrug activation gene therapy for cancer using cytochrome P450-4B1 and 2-amino-anthracene/4-ipomeanol. Hum. Gene Ther. (1998) 9:1261–1273.
   PubMed Web of Science ®Google Scholar
• HOGANSON DK, BATRA RK, OLSEN JC, BOUCHER RC:Comparison of the effects of three different toxin genes and their level of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. (1996) 56:1315–1323.
   PubMed Web of Science ®Google Scholar
• MULLEN CA, KILSTRUP M, BLAESE RM: Transfer of thebacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity of 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA (1992) 89:33–37.
   PubMed Web of Science ®Google Scholar
• SENTER PD, SU PCD, KATSURAGI T et al: Generation of5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Biocong. Chem. (1991) 2:447–451.
   PubMed Web of Science ®Google Scholar
• WALLACE PM, MACMASTER JF, SMITH VF et al.: Intratu-moral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate incombination with 5-fluorocytosine. Cancer Res. (1994) 54:2719–2723.
   PubMed Web of Science ®Google Scholar
• CHEN BM, CHAN LY, WANG SM, WU MF, CHERN JW, ROFFLER SR: Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of glucuronide prodrug in rats. Int. J. Cancer (1997) 73:392–402.
   PubMed Web of Science ®Google Scholar
• ROFFLER SR, WANG SM, CHERN JW, YEH MY, TUNG E:Anti-neoplastic glucuronide prodrug treatment of hu-man tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem. PharmacoL (1991) 42:2062–2065.
   PubMed Web of Science ®Google Scholar
• BAKINA E, WU Z, ROSENBLUM M, FARQUHAR D: In-tensely cytotoxic anthracycline prodrugs-glucuronides. J. Med. Chem. (1997) 40:4013–4018.
   PubMed Web of Science ®Google Scholar
• MEYER DL, LAW KL, PAYNE JK et al.: Site-specificprodrug activation by antibody-61actamase conju-gates: preclinical investigation of the efficacy and tox-icity of doxorubicin delivered by antibody directed catalysis. Biocong. Chem. (1995) 6:440–446.
   PubMed Web of Science ®Google Scholar
• SHEPHERD TA, JUNGHEIM LN, MEYER DM, STARLING JJ:A novel targeted delivery system utilising a cephalosporin-oncolytic prodrug activated by an anti-body-61actamase conjugate for the treatment of can-cer. Bioorg. Med. Chem. Lett. (1991) 1:21–26.
   Web of Science ®Google Scholar
• KERR DE, LI ZG, SIEMERS NO, SENTER PD, VRUDHULAVM: Development and activities of a new melphalan prodrug designed for tumor-selective activation. Bio-conjugate Chem. (1998) 9:255–259.
   PubMed Web of Science ®Google Scholar
• BRIDGEWATER JA, SPRINGER CJ, KNOX RJ, MINTON MP,MICHAEL NP, COLLINS MK: Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer (1995) 31a:2362–2370.
   Google Scholar
• BIGNAMI GS, SENTER PD, GROTHAUS PG, FISCHER KJ,HUMPHREYS T, WALLACE PM: N-(4'hydroxyphenylace-tyl) palytoxin: a palytoxin prodrug that can be acti-vated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res. (1992) 52:5759–5764.
   PubMed Web of Science ®Google Scholar
• VRUDHALA VM, SENTER PD, FISCHER KJ, WALLACE PM:Prodrugs of doxorubicin and melphalan and their ac-tivation by a monoclonal antibody-pencillin-G ami-dase conjugate. J. Med. Chem. (1993) 36:919–923.
   PubMed Web of Science ®Google Scholar
• BORELLI E, HEYMAN R, HSI M, EVANS RM: Targeting ofan inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci USA (1988) 85:7572–7576.
   PubMed Web of Science ®Google Scholar
• RAM Z, CULVER KW, WALBRIDGE S, FRANK JA, BLAESERM, OLDFIELD EH: Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tu-mors. J. Neurosurg. (1993) 79:400–407.
   PubMed Web of Science ®Google Scholar
• TONG XW, BLOCK A, CHEN SH et al.: In vivo gene ther-apy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol. (1996) 61:175–179.
   PubMed Web of Science ®Google Scholar